Steep, Sustained Lipid Reductions Over Statins With LIB003 Steep, Sustained Lipid Reductions Over Statins With LIB003

An open-label trial extension shows the novel anti-PCSK9 recombinant protein LIB003 markedly reduces lipid levels in heavily pretreated patients, although outcomes data are awaited, says expert.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news